Purchase
Description
Aflibercept biosimilar is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept biosimilar is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept biosimilar is produced in recombinant Chinese hamster ovary (CHO) cells.
Aflibercept biosimilar is supplied at a concentration of 40 mg/mL as a sterile, clear, and colorless to pale yellow solution, which contains 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 6.2.
Properties
|
Name
|
Aflibercept biosimilar
|
|
CAS
NO.
|
862111-32-8
|
|
Type
|
a recombinant fusion protein
|
|
Source
|
Human
|
|
Target
|
VEGF
|
|
Clone
|
Monoclone
|
|
Molecular
Weight
|
115 kDa
|
|
Formula
|
C4318H6788N1164O1304S32
|
|
Antibody
Form
|
Purified immunoglobulin
|
|
Physical
Form
|
Solution
|
|
Grade
Standard
|
Medicine Grade
|
|
Storage
|
-70±15℃ for long-term
storage, 2-8℃ for short-term storage, away from light.
|
Supply Ability
20 kilogram per year, Minimum order quantity is 1 gram.
Price
Inquiry
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
/en/UploadFile/file/201805/20180508153494759475.rar
Detail information about the product please refer the website below：
|
